Evaluation of rare and novel splicing variants in the RH system
Transfusion · 13.11.2026
DOI: 10.1111/trf.70480 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, online erschienen am 13.11.2026. Verfasst von Aline Floch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Immunohematology and Genomics Laboratory, New York Blood Center, Rye, New York, USA. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Single nucleotide variants near intron/exon junctions can affect RNA splicing, resulting in weak or loss of blood group antigen expression. We investigated 11 samples with no causative variants found in RH coding exons: three with weak RhD phenotypes and 8 with discordance between phenotypes and DNA prediction for RhCE.
Methods
Serologic and DNA testing was performed by standard methods. RH exons 1–10 and flanking introns were amplified and Sanger sequenced. Variants were evaluated using an in vitro splicing minigene assay.
Results
Three weak D phenotypes were associated with intron 1, RHD*149‐1G>A, or intron 3, RHD*487‐3C>A or RHD*487‐3C>G , variants. Splicing assay confirmed activation of a cryptic acceptor site for RHD*149‐1A , and both RHD*487‐3A and ‐3G resulted in mis‐splicing with minor amounts of normal transcripts. Among eight RHCE discrepancies: three had an intron 4 variant, RHCE*Ce c.635‐9G>A, causing a 7‐bp insertion, frameshift/stop; five had other intron variants, RHCE*cE c.336‐2A>G, RHCE*ce c.486+1G>A, RHCE*ce c.1154‐1G>A, RHCE*Ce c.939+1G>A, showing complete splicing disruption, and RHCE*Ce c.148+5G>T with no splicing disruption detectable.
Conclusions
Alleles studied here had intron variants associated with weak or absence of detectable antigen expression. Five are null alleles, RHCE*Ce635‐9A , RHCE*ce486+1A , RHCE*ce1154‐1A , RHCE*Ce148+5T , and RHCE*Ce939+1A , while RHCE*cE336‐2G is associated with E antigen detected by adsorption/elution. Splicing assays support RHD*149‐1A may encode an altered RhD, while the low level of normal splicing shown for RHD*487‐3A and RHD*487‐3G suggests very weak expression but the absence of alloimmunization risk. The minigene splicing assay offers insight into the effect of intron variants on antigen expression.
Autor:innen und Institutionen
- Immunohematology and Genomics Laboratory, New York Blood Center, Rye, New York, USA.
- Univ Paris Est Creteil, INSERM U955 Equipe « Transfusion et maladies du globule rouge », IMRB, Créteil, France.
- Laboratoire de biologie médicale en immunohématologie moléculaire, Etablissement francais du sang Ile-de-France, Créteil, France.
- Inserm, EFS, Univ Brest, UMR1078, GGB, Equipe Biomedicine and Integrative Genetics and Genomics (BIGG), Brest, France.
ORCID-Profile: Aline Floch, Sunitha Vege, Yann Fichou, Connie M Westhoff
Zitieren
APA
Floch, A., Vege, S., Gourlaouen, I., Fuertes, J., Lomas-Francis, C., Fichou, Y., & Westhoff, C. M. (2026). Evaluation of rare and novel splicing variants in the RH system. Transfusion. https://doi.org/10.1111/trf.70480
Vancouver
Floch A, Vege S, Gourlaouen I, Fuertes J, Lomas-Francis C, Fichou Y, et al. Evaluation of rare and novel splicing variants in the RH system. Transfusion. 2026. doi:10.1111/trf.70480
BibTeX
@article{Floch2026,
author = {Floch, Aline and Vege, Sunitha and Gourlaouen, Isabelle and Fuertes, June and Lomas-Francis, Christine and Fichou, Yann and Westhoff, Connie M},
title = {Evaluation of rare and novel splicing variants in the RH system},
journal = {Transfusion},
year = {2026},
doi = {10.1111/trf.70480}
}
EUVIMED